Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [21]
- Comments [0]
- Validations
- Western blot [1]
- Immunoprecipitation [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10060-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10060-1-AP, RRID:AB_2262677
- Product name
- FKBPL antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated FKBPL antibody (Cat. #10060-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Expression and role of FKBPL in lung adenocarcinoma.
Hsa_circ_0001402 alleviates vascular neointimal hyperplasia through a miR-183-5p-dependent regulation of vascular smooth muscle cell proliferation, migration, and autophagy.
E-Cigarette Aerosol Condensate Leads to Impaired Coronary Endothelial Cell Health and Restricted Angiogenesis.
A placenta-on-a-chip model to determine the regulation of FKBPL and galectin-3 in preeclampsia.
FK506-Binding Protein like (FKBPL) Has an Important Role in Heart Failure with Preserved Ejection Fraction Pathogenesis with Potential Diagnostic Utility.
Loss of Expression of Antiangiogenic Protein FKBPL in Endometrioid Endometrial Carcinoma: Implications for Clinical Practice.
FKBPL and SIRT-1 Are Downregulated by Diabetes in Pregnancy Impacting on Angiogenesis and Endothelial Function.
Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.
Characterisation of cardiac health in the reduced uterine perfusion pressure model and a 3D cardiac spheroid model, of preeclampsia.
Delivery of RALA/siFKBPL nanoparticles via electrospun bilayer nanofibres: An innovative angiogenic therapy for wound repair.
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
RALA-mediated delivery of FKBPL nucleic acid therapeutics.
FKBPL: a marker of good prognosis in breast cancer.
FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.
The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study.
Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling.
She L, Zhang X, Shen R, He S, Miao X
Journal of Cancer 2024;15(1):166-175
Journal of Cancer 2024;15(1):166-175
Hsa_circ_0001402 alleviates vascular neointimal hyperplasia through a miR-183-5p-dependent regulation of vascular smooth muscle cell proliferation, migration, and autophagy.
Lin JJ, Chen R, Yang LY, Gong M, Du MY, Mu SQ, Jiang ZA, Li HH, Yang Y, Wang XH, Wang SF, Liu KX, Cao SH, Wang ZY, Zhao AQ, Yang SY, Li C, Sun SG
Journal of advanced research 2024 Jun;60:93-110
Journal of advanced research 2024 Jun;60:93-110
E-Cigarette Aerosol Condensate Leads to Impaired Coronary Endothelial Cell Health and Restricted Angiogenesis.
Chhor M, Tulpar E, Nguyen T, Cranfield CG, Gorrie CA, Chan YL, Chen H, Oliver BG, McClements L, McGrath KC
International journal of molecular sciences 2023 Mar 28;24(7)
International journal of molecular sciences 2023 Mar 28;24(7)
A placenta-on-a-chip model to determine the regulation of FKBPL and galectin-3 in preeclampsia.
Ghorbanpour SM, Richards C, Pienaar D, Sesperez K, Aboulkheyr Es H, Nikolic VN, Karadzov Orlic N, Mikovic Z, Stefanovic M, Cakic Z, Alqudah A, Cole L, Gorrie C, McGrath K, Kavurma MM, Ebrahimi Warkiani M, McClements L
Cellular and molecular life sciences : CMLS 2023 Jan 18;80(2):44
Cellular and molecular life sciences : CMLS 2023 Jan 18;80(2):44
FK506-Binding Protein like (FKBPL) Has an Important Role in Heart Failure with Preserved Ejection Fraction Pathogenesis with Potential Diagnostic Utility.
Chhor M, Chen H, Jerotić D, Tešić M, Nikolić VN, Pavlović M, Vučić RM, Rayner B, Watson CJ, Ledwidge M, McDonald K, Robson T, McGrath KC, McClements L
Biomolecules 2023 Feb 18;13(2)
Biomolecules 2023 Feb 18;13(2)
Loss of Expression of Antiangiogenic Protein FKBPL in Endometrioid Endometrial Carcinoma: Implications for Clinical Practice.
Obradović DD, Milić NM, Miladinović N, McClements L, Oprić DM
Medicina (Kaunas, Lithuania) 2022 Sep 22;58(10)
Medicina (Kaunas, Lithuania) 2022 Sep 22;58(10)
FKBPL and SIRT-1 Are Downregulated by Diabetes in Pregnancy Impacting on Angiogenesis and Endothelial Function.
Alqudah A, Eastwood KA, Jerotic D, Todd N, Hoch D, McNally R, Obradovic D, Dugalic S, Hunter AJ, Holmes VA, McCance DR, Young IS, Watson CJ, Robson T, Desoye G, Grieve DJ, McClements L
Frontiers in endocrinology 2021;12:650328
Frontiers in endocrinology 2021;12:650328
Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.
Todd N, McNally R, Alqudah A, Jerotic D, Suvakov S, Obradovic D, Hoch D, Hombrebueno JR, Campos GL, Watson CJ, Gojnic-Dugalic M, Simic TP, Krasnodembskaya A, Desoye G, Eastwood KA, Hunter AJ, Holmes VA, McCance DR, Young IS, Grieve DJ, Kenny LC, Garovic VD, Robson T, McClements L
The Journal of clinical endocrinology and metabolism 2021 Jan 1;106(1):26-41
The Journal of clinical endocrinology and metabolism 2021 Jan 1;106(1):26-41
Characterisation of cardiac health in the reduced uterine perfusion pressure model and a 3D cardiac spheroid model, of preeclampsia.
Richards C, Sesperez K, Chhor M, Ghorbanpour S, Rennie C, Ming CLC, Evenhuis C, Nikolic V, Orlic NK, Mikovic Z, Stefanovic M, Cakic Z, McGrath K, Gentile C, Bubb K, McClements L
Biology of sex differences 2021 Apr 20;12(1):31
Biology of sex differences 2021 Apr 20;12(1):31
Delivery of RALA/siFKBPL nanoparticles via electrospun bilayer nanofibres: An innovative angiogenic therapy for wound repair.
Mulholland EJ, Ali A, Robson T, Dunne NJ, McCarthy HO
Journal of controlled release : official journal of the Controlled Release Society 2019 Dec 28;316:53-65
Journal of controlled release : official journal of the Controlled Release Society 2019 Dec 28;316:53-65
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F, Short A, McIntosh SA, McCarthy HO, Clarke RB, Robson T
BMC cancer 2019 Apr 11;19(1):351
BMC cancer 2019 Apr 11;19(1):351
RALA-mediated delivery of FKBPL nucleic acid therapeutics.
Bennett R, Yakkundi A, McKeen HD, McClements L, McKeogh TJ, McCrudden CM, Arthur K, Robson T, McCarthy HO
Nanomedicine (London, England) 2015 Oct;10(19):2989-3001
Nanomedicine (London, England) 2015 Oct;10(19):2989-3001
FKBPL: a marker of good prognosis in breast cancer.
Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T
Oncotarget 2015 May 20;6(14):12209-23
Oncotarget 2015 May 20;6(14):12209-23
FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
Yakkundi A, Bennett R, Hernández-Negrete I, Delalande JM, Hanna M, Lyubomska O, Arthur K, Short A, McKeen H, Nelson L, McCrudden CM, McNally R, McClements L, McCarthy HO, Burns AJ, Bicknell R, Kissenpfennig A, Robson T
Arteriosclerosis, thrombosis, and vascular biology 2015 Apr;35(4):845-54
Arteriosclerosis, thrombosis, and vascular biology 2015 Apr;35(4):845-54
Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.
Donley C, McClelland K, McKeen HD, Nelson L, Yakkundi A, Jithesh PV, Burrows J, McClements L, Valentine A, Prise KM, McCarthy HO, Robson T
Oncogene 2014 Jun 26;33(26):3441-50
Oncogene 2014 Jun 26;33(26):3441-50
The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.
Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO, Hirst DG, Robson T
PloS one 2013;8(2):e55075
PloS one 2013;8(2):e55075
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Mar 1;17(5):1044-56
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Mar 1;17(5):1044-56
Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study.
Sunnotel O, Hiripi L, Lagan K, McDaid JR, De León JM, Miyagawa Y, Crowe H, Kaluskar S, Ward M, Scullion C, Campbell A, Downes CS, Hirst D, Barton D, Mocanu E, Tsujimura A, Cox MB, Robson T, Walsh CP
Reproductive biology and endocrinology : RB&E 2010 Mar 8;8:22
Reproductive biology and endocrinology : RB&E 2010 Mar 8;8:22
Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.
Bublik DR, Scolz M, Triolo G, Monte M, Schneider C
The Journal of biological chemistry 2010 Feb 19;285(8):5274-81
The Journal of biological chemistry 2010 Feb 19;285(8):5274-81
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, O'Rourke M, Swanton C, McCarthy HO, Hirst DG, Robson T
Cancer research 2010 Feb 1;70(3):1090-100
Cancer research 2010 Feb 1;70(3):1090-100
A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling.
McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, O'Rourke M, Young S, Scott CJ, McCarthy HO, Hirst DG, Robson T
Endocrinology 2008 Nov;149(11):5724-34
Endocrinology 2008 Nov;149(11):5724-34
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- MCF7 cells were subjected to SDS PAGE followed by western blot with 10060-1-AP(FKBPL antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- IP Result of anti-FKBPL (IP:10060-1-AP, 3ug; Detection:10060-1-AP 1:800) with MCF-7 cells lysate 2500ug.
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human testis using 10060-1-AP(FKBPL antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The FKBPL antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human FKBPL. This antibody recognizes human,mouse,rat antigen. The FKBPL antibody has been validated for the following applications: ELISA, WB, IHC, IP analysis.
